- Home
- APLM vs NLSP Comparison
APLM vs NLSP Comparison
Compare APLM & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- NLSP
- Stock Information
- Founded
- APLM 2016
- NLSP 2015
- Country
- APLM United States
- NLSP Switzerland
- Employees
- APLM N/A
- NLSP N/A
- Industry
- APLM Blank Checks
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- APLM Finance
- NLSP Health Care
- Exchange
- APLM Nasdaq
- NLSP Nasdaq
- Market Cap
- APLM 7.7M
- NLSP 6.9M
- IPO Year
- APLM N/A
- NLSP 2021
- Fundamental
- Price
- APLM $6.71
- NLSP $1.49
- Analyst Decision
- APLM Strong Buy
- NLSP
- Analyst Count
- APLM 2
- NLSP 0
- Target Price
- APLM $425.00
- NLSP N/A
- AVG Volume (30 Days)
- APLM 42.6K
- NLSP 29.9K
- Earning Date
- APLM 04-15-2025
- NLSP 05-14-2025
- Dividend Yield
- APLM N/A
- NLSP N/A
- EPS Growth
- APLM N/A
- NLSP N/A
- EPS
- APLM N/A
- NLSP N/A
- Revenue
- APLM $2,101,000.00
- NLSP N/A
- Revenue This Year
- APLM N/A
- NLSP N/A
- Revenue Next Year
- APLM N/A
- NLSP N/A
- P/E Ratio
- APLM N/A
- NLSP N/A
- Revenue Growth
- APLM 70.54
- NLSP N/A
- 52 Week Low
- APLM $6.20
- NLSP $1.30
- 52 Week High
- APLM $63.00
- NLSP $18.40
- Technical
- Relative Strength Index (RSI)
- APLM 43.33
- NLSP 42.38
- Support Level
- APLM $6.20
- NLSP $1.30
- Resistance Level
- APLM $8.00
- NLSP $1.60
- Average True Range (ATR)
- APLM 1.37
- NLSP 0.11
- MACD
- APLM -0.18
- NLSP 0.02
- Stochastic Oscillator
- APLM 9.44
- NLSP 54.29
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.